Effect of the Tang herb on the pharmacokinetics of lopinavir in rats

doi:10.5246/jcps.2014.01.004

Abstract

Abstract:

This study was carried out in the Wistar rats to investigate the effect of Tang herb on the pharmacokinetics of the antiretroviral drug lopinavir (LPV) following single oral administration. Rats were randomly divided into LPV group (36 mg/kg) and LPV combining with Tang herb group (LPV: 36 mg/kg, Tang herb: 864 mg/kg). The blood concentrations of lopinavir at 0, 0.5, 1, 2, 4, 8, 10, 12, 14, 16, 22 h after administration were determined by HPLC and the pharmacokinetic parameters were investigated. The results showed that Tang herb significantly increased the C_max and AUC (P<0.05) while slightly increased the t_1/2z and T_maxof lopinavir (P>0.05). The present study suggests that Tang herb may delay the absorption, increase the time to reach the maximum concentration, and improve the bioavailability of LPV. Further evaluation of the possible interaction mechanism between Tang herb and LPV needs to be studied.

Key words: Pharmacokinetics, Interaction, Lopinavir, Tang herb

CLC Number:

R962

Supporting:

Yamin Yao*, Jun Mu, Ji Sun, Lin Yin, Jun Chen, Hongzhou Lu, Lijun Zhang. Effect of the Tang herb on the pharmacokinetics of lopinavir in rats[J]. Journal of Chinese Pharmaceutical Sciences, 2014, 23(1): 28-32.

References

[1] Chu, Y.; Liu, H. Adv. Dent. Res. 2011, 23, 67–75.

[2] Langlois-Klassen, D.; Kipp, W.; Rubaale, T. Soc. Sci. Med. 2008, 67, 165–176.

[3] Dhalla, S.; Chan, K.J.; Montaner, J.S.; Hogg, R.S. Complement. Ther. Clin. Pract. 2006, 12, 242–248.

[4] Peltzer, K.; Preez, N.F.; Ramlagan, S.; Fomundam, H. BMC Public Health. 2008, 8, 255.

[5] Li, R.; Li, J. Anhui Med. Pharm. J. 2005, 9, 481–483.

[6] Olthof, M.R.; Hollman, P.C.; Katan, M.B. J. Nutr. 2001, 131, 66–71.

[7] Marzolini, C.; Telenti, A.; Decosterd, L.A.; Greub, G.; Biollaz, J.; Buclin, T. AIDS. 2001, 15, 71–75.

[8] Durant, J.; Clevenbergh, P.; Garraffo, R.; Halfon, P.; Icard, S.; Del Giudice, P.; Montagne, N.; Schapiro, J.M.; Dellamonica, P. AIDS. 2000, 14, 1333–1339.

[9] Colombo, S.; Telenti, A.; Buclin, T.; Furrer, H.; Lee, B.L.; Biollaz, J.; Decosterd, L.A. Ther. Drug Monit. 2006, 28, 332–338.

[10] Fletcher, C.V.; Kawle, S.P.; Kakuda, T.N.; Anderson, P.L.; Weller, D.; Bushman, L.R.; Brundage, R.C.; Remmel, R.P. AIDS. 2000, 14, 2137–2144.

[11] Li, A.M.; Liu, X.Y.; Wang, X.W.; Liu, J.Y. J. Chin. Pharm. Sci. 2011, 20, 447–453.

[12] Chen, J.; Zhang, L.J.; Yao, Y.M.; Wang, J.R.; Sun, F.Y.; Qi, T.K.; Li, L.; Lu, H.Z. Chin. J. Aids. Std. 2012, 18, 645–647.

[13] Slish, J.C.; Catanzaro, L.M.; Ma, Q.; Okusanya, O.O.; Demeter, L.; Albrecht, M.; Morse, G.D. Curr. Pharm. Des. 2006, 12, 1129–1145.

[14] van Waterschoot, R.A.; ter Heine, R.; Wagenaar, E.; van der Kruijssen, C.M.; Rooswinkel, R.W.; Huitema, A.D.; Beijnen, J.H.; Schinkel, A.H. Br. J. Pharmacol. 2010, 160, 1224–1233.

[15] Pal, D.; Mitra, A.K. Life Sci. 2006, 78, 2131–2145.

[16] Limtrakul, P.; Khantamat, O.; Pintha, K. J. Chemother. 2005, 17, 86–95.

[17] Sarkar, M.A. Cancer Chemother. Pharmacol. 1995, 36, 448–449.

[18] Cao, Y.; Wu, K.C.; Yang, Z.G.; Sun, J.B.; Zhang, X.; Zhang, Q. Chin. Hosp. Pharm. J. 2007, 27, 877–880.

[19] Xu, W.; Sun, S.H.; Liu, T.; Ma, M.; Sui, Z.G. China Licensed Pharmacist. 2012, 9, 3–5.

[20] Yao, Y.M.; Sun, J.J.; Chen, J.; Liu, X.Q.; Lu, H.Z.; Zhang, L.J. Acta Pharm. Sin. 2010, 45, 279–282.

[21] Yadav, M.; Rao, R.; Kurani, H.; Singhal, P.; Goswami, S.; Shrivastav, P.S. J. Pharm. Biomed. Anal. 2009, 49, 1115–1122.

[22] Rajasekhar, D.; Jaswanthumar, I.; Ravi, K.; Srinivasulu, P.; Venkateswarlu, P. Chromatographia. 2010, 71,